• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Roche no longer wants to be where ‘DNA se­quenc­ing goes to die’

3 months ago
R&D
Diagnostics

In­side the Ac­co­lade-Tran­scar­ent deal

3 months ago
Health Tech

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

3 months ago
FDA+

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

3 months ago
Startups
Deals

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

3 months ago
R&D

Why Unit­ed­Health Group is of­fer­ing 30,000 vol­un­tary buy­outs to its em­ploy­ees

3 months ago
Health Tech

Charles Riv­er’s $1B rev­enue; Ther­at­e­ch­nolo­gies restarts HIV drug sup­ply

3 months ago
Manufacturing

Il­lu­mi­na to lay off about 100 peo­ple; In­cyte’s new AI part­ner­ship

3 months ago
News Briefing

Trump’s picks for NIH, CMS say they’ll un­load in­dus­try in­vest­ments

3 months ago
People
Pharma

Drug pack­ag­ing man­u­fac­tur­ers brace for im­pact as EU chem­i­cal ban looms

3 months ago
Manufacturing

As­traZeneca buys Fi­bro­Gen’s Chi­na unit for lo­cal con­trol of ane­mia drug

3 months ago
Deals
China

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

3 months ago
Pharma

Paris start­up col­lects €27M in Se­ries B to ad­vance over­ac­tive blad­der treat­ment

3 months ago
Financing
Startups

Can amylin drugs take over from GLP-1s in obe­si­ty? Part­ner­less Zealand thinks so

3 months ago
R&D

Hims buys at-home test­ing com­pa­ny Trybe Labs

3 months ago
Deals
Health Tech

Up­dat­ed: Fed­er­al gov­ern­ment de­fends lab-de­vel­oped test rule in Texas court

3 months ago
Pharma
Law

Nvidia and the Arc In­sti­tute just dropped a re­al­ly, re­al­ly big AI bio mod­el 

3 months ago
AI

As­cle­tis’ obe­si­ty pill looks sim­i­lar to Roche’s drug, ear­ly da­ta sug­gest

3 months ago
R&D

An­oth­er Chi­nese biotech files to go pub­lic in Hong Kong; A new ROR1 ADC deal

3 months ago
News Briefing

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

3 months ago
Pharma

Will CRISPR mat­ter?

3 months ago
R&D
Special

Bare foot­prints and blocked in­spec­tors: FDA places two In­di­an man­u­fac­tur­ers on im­port alerts

3 months ago
FDA+
Manufacturing

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

3 months ago
FDA+

Start­up that mines ‘junk DNA’ se­cures R&D deal with Mer­ck

3 months ago
Startups
Deals
First page Previous page 40414243444546 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times